SWK Holdings Corporation Announces 2019 First Quarter Financial Results

GlobeNewswire |
  • Total revenues of approximately $9.4 million for the first quarter of 2019 compared to $6.8 million for the first quarter of 2018.

  • Net income of $6.6 million, or $0.51 per share, and non-GAAP Adjusted net income of $7.4 million, or $0.57 per share for the first quarter of 2019.

  • Closed two financings deploying $11.2 million. Post quarter close deployed $5.0 million with potential additional add-on funding of $7.5 million to existing portfolio companies.

  • Book value of $16.98 per share as of vs. $16.47 per share as of .

DALLAS, (GLOBE NEWSWIRE) -- SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced its first quarter 2019 financial results.

First Quarter 2019 Highlights:

  • Reported total revenues of approximately $9.4 million for the quarter, compared to $6.8 million for the first quarter of 2018.

  • Reported adjusted net income of approximately $7.4 million, or $0.57 per diluted share, for the quarter, as compared to $4.4 million, or $0.34 per diluted share, for the first quarter of 2018.

  • Total income producing assets (defined as finance receivables and corporate debt securities) were approximately $154.9 million as of , compared to $167.1 million as of .

  • Repurchased 77,300 shares during the quarter at an average cost of $9.63 per share. Since SWK has repurchased 222,366 shares at an average cost of $9.68 per share. 

“We are pleased with the strong first quarter results highlighted by the closing of two new transactions, as well as, advancing additional capital to current partners subsequent to quarter close.” stated Winston Black, Chief Executive Officer of SWK. “We are also pleased to support the pending acquisition of Solsys Medical LLC by Misonix Inc. via an upsized facility. We anticipate closing additional deals during the balance of the year and remain highly focused on increasing shareholder value."


  • All references to growth rate percentages and shares compare the results of the period to those of the prior year comparable period.

  • The Company reports its financial results in accordance with Generally Accepted Accounting Principles in the U.S. (“GAAP”).  However, management believes that certain non-GAAP financial measures provide users with additional meaningful financial information that should be considered when assessing the Company’s ongoing performance. Non-GAAP financial measures should be viewed in addition to, and not as an alternative for, the Company’s reported results prepared in accordance with GAAP. The Company’s non-GAAP financial information does not represent a comprehensive basis of accounting. Management also uses these non-GAAP financial measures in making financial, operating and planning decisions and in evaluating the Company's performance.

  • Non-GAAP Adjusted net income and its components and Non-GAAP Adjusted basic and diluted EPS are not, and should not be viewed as, substitutes for GAAP net income and its components and basic and diluted EPS. Despite the importance of these measures to management in goal setting and performance measurement, we stress that these are Non-GAAP financial measures that have no standardized meaning prescribed by GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, Non-GAAP Adjusted net income and its components (unlike GAAP net income and its components) may not be comparable to the calculation of similar measures of other companies.

Portfolio Overview

As of , the Company's total income producing assets were approximately $154.9 million as compared to $167.1 million as of .

(in thousands) , ,
  2019 2018
Finance receivables $154,410  $166,610 
Corporate debt securities 511  532 
Less non-controlling interest    
Total income producing assets $154,921  $167,142 
Warrant Assets 3,057  2,777 
Total Portfolio Balance $157,978  $169,919 

During the quarter, the Company deployed $10.0 million via a new term loan to Cheetah Medical, Inc. and $1.2 million through the participation in a term loan to Aimmune Therapeutics, Inc., for a total of $11.2 million.  These deployments were offset by a $20.0 million repayment of the EyePoint Pharmaceuticals term loan.

Post quarter close, SWK supported BIOLASE, Inc.’s capital needs through an additional $2.5 million of funding. The Company also helped facilitate the merger of Solsys Medical, LLC (“Solsys”) and Misonix, Inc. (“Misonix”) by advancing Solsys an incremental $2.5 million, with an additional $2.5 million if certain conditions are achieved; SWK also committed to advance Misonix an additional $5.0 million post consummation of the merger, if closed.   

As of , the Company and its partners have executed transactions with 34 different parties under its specialty finance strategy, funding an aggregate $499 million since 2012 in various financial products across the life science sector.  At the end of the third quarter, the weighted average projected effective yield of the finance receivables portfolio was 15.0%.  The projected effective yield is the rate at which income is expected to be recognized pursuant to the Company’s revenue recognition policies, if all payments are received pursuant to the terms of the finance receivables.

Total portfolio investment activity as of and for the three months ended was as follows (in thousands):

 Three Months Ended
 2019 2018
Beginning portfolio$169,919   $154,838  
Impairment expense and provision for loan credit losses(609)  (1,179) 
Interest paid-in-kind406   47  
Investment in finance receivables11,186   29,250  
Loan discount amortization and fee accretion681   649  
Net unrealized gain (loss) on marketable investments and derivatives280   151  
Principal payments received on investments(20,906)  (716) 
Royalty paydowns(2,979)  (14,222) 
Warrant investments, net of cancellations   258  
Ending portfolio$157,979   $169,334  

Update on Share Repurchase Program

On , SWK implemented the $3.5 million share repurchase program, or approximately 312,491 common shares,  that its Board of Directors authorized to be executed in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Securities Exchange Act. The purchase period is through

As of , the Company has repurchased 222,366 shares of its outstanding shares of common stock. Of the total 222,366 shares, 137,800 were repurchased under the share repurchase program at a total cost of $1.3 million, or $9.58 per share. As of , the maximum number of shares that may yet be purchased under the plan is 174,691 shares.

Results of Operations


We generated revenues of $9.4 million and $6.8 million for the three months ended and 2018, respectively, which consisted of interest and fees earned on our finance receivables. The increase in revenue is primarily due to a $2.5 million increase in interest and fees earned on new and existing finance receivables and $3.4 million in exit and prepayment fees from a loan payoff. The increase in revenue was offset by a $2.6 million decrease in interest and fees earned on finance receivables that were paid off or paid down in 2018.

Provision for Credit Losses and Impairment Expense

During the three months ended , we recognized credit loss provision expense of $0.6 million related to the Besivance® royalty, which was due to increases in sales chargebacks and various rebates (gross sales to net sales deductions) and lower sales volumes. We recognized an allowance for credit losses on a royalty of $1.2 million during the three months ended . Please refer to Part I. Financial Information, Item 1. Financial Statements, Note 3 of the Notes to the Unaudited Condensed Consolidated Financial Statements for further information on the provision for credit losses recognized during the three months ended .

General and Administrative

General and administrative expenses consist primarily of compensation, stock-based compensation and related costs for management, staff, Board of Directors, legal and audit expenses, and corporate governance. General and administrative expenses increased to $1.3 million for the three months ended from $1.2 million for the three months ended , which was primarily due to an increase in the performance-based bonus accrual.

Other Income (Expense), Net
Other income for the three months ended reflected a net fair market value gain of $0.3 million on our warrant derivatives. Other income for the three months ended , reflected a net fair market value gain of $0.3 million on our warrant derivatives and a net fair market value loss of $0.1 million on our equity securities.

Income Tax (Benefit) Expense
We recognized deferred income tax expense of $1.1 million and $1.0 million during the three months ended and 2018, respectively. The increase in deferred income tax expense was primarily due to an increase in net income.

Liquidity and Capital Resources

As of , we had $39.2 million in cash and cash equivalents, compared to $20.2 million in cash and cash equivalents as of . The primary driver of the net increase in our cash balance was $23.3 million related to the payoff of one finance receivable, offset by new and add-on investment funding of $11.2 million.

As of , we had $5.8 million of unfunded commitments outstanding.  Subsequent to quarter close a $2.0 million unfunded commitment to Veru was eliminated while a $2.5 million unfunded commitment to Solsys Medical was signed.   

Adjusted Net Income

Net income in accordance with GAAP for the three month period ended , was $6.6 million, or $0.51 per diluted share. The table below eliminates provisions for income taxes, non-cash mark-to-market changes on warrant assets and SWK's warrant liability.

The following tables provide a reconciliation of SWK’s reported (GAAP) consolidated net income to SWK’s adjusted net income attributable to SWK Holdings Corporation Stockholders (Non-GAAP) for the three ended and :

(in thousands, except per share data) Three Months Ended
  2019 2018
Consolidated net income $6,559   $3,644 
Plus: income tax (benefit) expense 1,111   954 
Plus: loss on fair market value of equity securities    124 
Subtract: gain on fair market value of warrant assets (258)  (300)
Plus: gain on realized value of warrants     
Adjusted income before provision for income tax

 7,412   4,422 
Adjusted provision for income tax     
Non-GAAP consolidated net income 7,412    4,422 
Non-GAAP adjusted net income attributable to non-controlling interest    0 
Non-GAAP adjusted net income attributable to SWK Holdings Corporation Stockholders $7,412   $4,422 
Non-GAAP adjusted basic income per share $0.57   $0.34 
Non-GAAP adjusted diluted income per share $0.57   $0.34 
Weighted average shares - Basic 12,906   13,053 
Weighted average shares - Diluted 12,909   13,057 

In the presentation above, management has deducted the following non-cash items: (i) fair-market value of warrants as mark to market changes are non-cash, and (ii) income taxes as the Company has substantial net operating losses to offset against future income.

About SWK Holdings Corporation

SWK Holdings Corporation is a specialized finance company with a focus on the global healthcare sector.  SWK partners with ethical product marketers and royalty holders to provide flexible financing solutions at an attractive cost of capital to create long-term value for both SWK’s business partners and its investors.  SWK believes its financing structures achieve an optimal partnership for companies, institutions and inventors seeking capital for expansion or capital and estate planning by allowing its partners to monetize future cash flow with minimal dilution to their equity stakes. Additional information on the life science finance market is available on the Company’s website at www.swkhold.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as “believes,” “expects,” “anticipates,” “intends,” “estimates,” “plan,” “will,” “may,” “look forward,” “intend,” “guidance,” “future” or similar expressions are forward-looking statements. Because these statements reflect SWK’s current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption “Risk Factors” in SWK’s Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein, could affect the Company’s future financial results and could cause actual results to differ materially from those expressed in such forward-looking statements. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause the Company’s actual results to differ materially from expected and historical results. You should not place undue reliance on any forward-looking statements, which speak only as of the date they are made.  We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

(in thousands, except par value and share data)
Derived from unaudited financial statements
Cash and cash equivalents$39,183  $20,227 
Interest receivable1,930  2,195 
Finance receivables, net154,410  166,610 
Corporate debt securities511  532 
Deferred tax asset21,573  22,684 
Warrant assets3,057  2,777 
Other assets645  637 
Total assets$221,309  $215,662 
Accounts payable and accrued liabilities$2,301  $2,592 
Warrant liability35  13 
Total liabilities2,336  2,605 
Stockholders’ equity:   
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued
and outstanding as of and , respectively
Common stock, $0.001 par value; 250,000,000 shares authorized; 12,898,599
and 12,933,674 shares issued and outstanding as of and
, respectively
13  13 
Additional paid-in capital4,431,856  4,432,499 
Accumulated deficit(4,212,896) (4,219,455)
Total stockholders’ equity218,973  213,057 
Total liabilities and stockholders’ equity$221,309  $215,662 

(in thousands, except per share data)
Derived from unaudited financial statements
 Three Months Ended
  2019 2018
Finance receivable interest income, including fees$9,391  $6,817 
Other 1  5 
Total revenues 9,392  6,822 
Costs and expenses:   
Provision for credit losses 609  1,179 
Interest Expense 102   
General and administrative 1,269  1,221 
Total costs and expenses 1,980  2,400 
Other income (expense), net   
Unrealized net gain on warrants 258  300 
Unrealized net loss on equity securities   (124)
Income before provision for income taxes 7,670  4,598 
Provision for income taxes 1,111  954 
Consolidated net income 6,559  3,644 
Net income per share   
Basic$  0.51  $0.28 
Diluted$  0.51  $0.28 
Weighted Average Shares   
Basic 12,906  13,053 
Diluted 12,909  13,057 

(in thousands)
Derived from unaudited financial statements
 Three Months Ended
 2019 2018
Cash flows from operating activities:   
Consolidated net income$6,559  $3,644 
Adjustments to reconcile net income to net cash provided by operating activities:   
Provision for loan credit losses609  1,179 
Deferred income taxes1,111  954 
Change in fair value of warrants(258) (300)
Change in fair value of equity securities  124 
Loan discount amortization and fee accretion(600) (837)
Interest paid-in-kind(406) (47)
Stock-based compensation102  79 
Interest income in excess of cash received(81) (70)
Other(1) 4 
Changes in operating assets and liabilities:   
Interest receivable265  58 
Other assets(9) (189)
Accounts payable and other liabilities(291) 610 
Net cash provided by operating activities7,000  5,209 
Cash flows from investing activities:   
Investment in finance receivables(11,186) (29,250)
Repayment of finance receivables23,866  14,918 
Corporate debt security principal payment21  19 
Other  (2)
Net cash provided by (used in) investing activities12,701  (14,315)
Cash flows from financing activities:   
Repurchases of common stock, including fees and expenses(745)  
Net cash used in financing activities(745)  
Net increase (decrease) in cash and cash equivalents18,956  (9,106)
Cash and cash equivalents at beginning of period20,227  30,557 
Cash and cash equivalents at end of period$39,183  $21,451 

CONTACT: SWK Investor Relations at (972) 687-7250 or investor.relations@swkhold.com.

SWK Holdings logo

Source: SWK Holdings Corporation

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer



Symbol Last Price Change % Change










World Economic Forum at Davos 2019 - Dominic Briggs General Partner Blockwall Management

Matt Bird sits down with Dominic Briggs, General Partner Blockwall Management at the World Economic Forum at Davos 2019